Skip to content
Screener

BioCryst Pharmaceuticals BCRX Exercise of warrants

Exercise of warrants at other companies

KEE
Keel InfrastructureKEEL
15.2M+197%
KEE
Keel InfrastructureKEEL
15.2M+197%
DraftKings Inc. logo
DraftKings Inc.DKNG
$0-100%
DraftKings Inc. logo
DraftKings Inc.DKNG
$0-100%
Laser Photonics Corporation logo
Laser Photonics CorporationLASE
$61.97K
JFB Construction Holdings logo
JFB Construction HoldingsJFB
$4-11.1%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.31B+27.7%
Enterprise value$2.56B+29.8%
P/S2.5×-0.8×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:StockIssuedDuringPeriodValueExerciseOfWarrants.

The source filing: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 4:03 PM EST
Fiscal year
FY2025
Accession
0001628280-26-012240
Line itemCommon Stock / SharesCommon Stock / AmountAdditional Paid-In CapitalAccumulated Other Comprehensive IncomeAccumulated DeficitTotal Stockholders’Deficit
Vesting of restricted stock units1,27613(13)
Shares withheld for taxes for vesting of restricted stock units(59)(1)(369)(370)
Employee stock purchase plan sales33842,5922,596
Exercise of warrants14,997150(150)
Issuance of shares to directors in lieu of cash retainer37342342
Stock-based compensation expense55,61555,615
Balance at December 31, 2023205,771$2,058$1,222,236$1,337$(1,681,159)$(455,528)
Net loss(88,881)(88,881)

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FAQ

What is BioCryst Pharmaceuticals's exercise of warrants?
BioCryst Pharmaceuticals (BCRX) reported exercise of warrants of $0 in Q4 2023.
What does exercise of warrants mean?
Exercise of warrants as reported by BioCryst Pharmaceuticals Inc.

Ask your AI about BioCryst Pharmaceuticals's exercise of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude